EPALINGES, Switzerland, June 4, 2015 – Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, will present three scientific posters at the 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015 (Barcelona, June 6-10,2015). All posters will focus on Anergis´ birch pollen immunotherapeutic AllerT, featuring detailed clinical data as well as in vitro and in vivo safety and immunogenicity data. AllerT is Anergis´ most advanced product and based on the company´s proprietary Contiguous Overlapping Peptide (COP) platform.

The following scientific communications will be presented at the EAACI Conference 2015:

Presentation Title: "Phase IIb follow-up trial of sustained efficacy of AllerT allergy vaccine during a second birch pollen season"
Presenter: Gilles Della Corte
Time and Date: Sunday, June 7, 2015, at 02:06pm CET
Session: Oral Abstract Session OAS 10 AIT: Efficacy and clinical outcomes
Abstract #: 327

Presentation Title: "Persistence of anti-Bet v 1 IgG4 prior and during a second pollen season after AllerT ultra-fast immunotherapy (phase IIb follow up)"
Presenter: Dr. Christophe Reymond
Time and Date: Tuesday, June 9, 2015, at 10:30am CET
Session: Poster Discussion Session PDS 25: Immunotherapy vaccines
Abstract #: 530

Presentation Title: "Requirement for aluminium hydroxide as adjuvant for successful ultra-fast immunotherapy with AllerT"
Presenter: Dr. Alexander Kettner
Time and Date: Monday, June 8, 2015, at 12:00pm CET
Session: Thematic Poster Session TPS 32: Allergen standardization
Abstract #: 1141

Contact

  • Biopôle III, Route de la Corniche 9B
    CH-1066 Epalinges
  • Email:
Top

This website uses cookies to ensure you get the best experience on our website.